CP and leukoplakia: After 4 months of therapy, according to IGA and DLQI assessment, all patients (group A; n = 14) treated with PDRN + CP showed drastic improvement of the various signs of the disease, related to different aspects of LS, such as hypertrophy, atrophy, leukoplakia, erosion, pigmentation, and inflammation, as compared to patients (group B; n = 14) treated with topical CP therapy.